Sam Lazzara
Trusted Information Resource
Does anybody else see a "problem" here?
It appears to me that the proposed signature requirements for the "Control of records 820.35" is very burdensome as compared to the existing requirements for signatures in the current 820 regulation.
Signature requirements in current FDA 21 CFR 820 (as of 2022-03)
820.30 Design controls (c) Design input
820.30 Design controls (d) Design output
820.40 Document controls.
820.75 Process validation
820.80 Receiving, in-process, and finished device acceptance
820.120 Device labeling (b) Labeling inspection
820.90 Nonconforming product (b) Nonconformity review and disposition
Signature requirements in ISO 13485:2016
None
Signature requirements in "proposed" FDA 21 CFR 820 QMS Regulation
All records (?) (see proposal below)
§ 820.35 Control of records.
In addition to the requirements of Clause 4.2.5 in ISO 13485 (incorporated by reference, see § 820.7), Control of
Records, the manufacturer must obtain the signature for each individual who approved or re-approved the record, and
the date of such approval, on that record and include the below information in certain records as follows: ....
https://www.govinfo.gov/content/pkg/FR-2022-02-23/pdf/2022-03227.pdf
My Analysis
ISO 13485:2016 clause 4.2.5 applies to all QMS records but in no case are signatures required per ISO 13485. The FDA proposed 820 rule (QMSR) appears to require signatures/dates for ALL QMS records, not only the documents/records that required signatures per the current 820 regulation. For my clients who do not employ eQMS software, this would be a substantial and burdensome change. Their general practice for the documents/records not requiring signature per the current 820 regulation is to simply enter the name of the responsible person and the date on the document/record, and not to require a signature (handwritten or electronic) for those documents/records.
It appears to me that the proposed signature requirements for the "Control of records 820.35" is very burdensome as compared to the existing requirements for signatures in the current 820 regulation.
Signature requirements in current FDA 21 CFR 820 (as of 2022-03)
820.30 Design controls (c) Design input
820.30 Design controls (d) Design output
820.40 Document controls.
820.75 Process validation
820.80 Receiving, in-process, and finished device acceptance
820.120 Device labeling (b) Labeling inspection
820.90 Nonconforming product (b) Nonconformity review and disposition
Signature requirements in ISO 13485:2016
None
Signature requirements in "proposed" FDA 21 CFR 820 QMS Regulation
All records (?) (see proposal below)
§ 820.35 Control of records.
In addition to the requirements of Clause 4.2.5 in ISO 13485 (incorporated by reference, see § 820.7), Control of
Records, the manufacturer must obtain the signature for each individual who approved or re-approved the record, and
the date of such approval, on that record and include the below information in certain records as follows: ....
https://www.govinfo.gov/content/pkg/FR-2022-02-23/pdf/2022-03227.pdf
My Analysis
ISO 13485:2016 clause 4.2.5 applies to all QMS records but in no case are signatures required per ISO 13485. The FDA proposed 820 rule (QMSR) appears to require signatures/dates for ALL QMS records, not only the documents/records that required signatures per the current 820 regulation. For my clients who do not employ eQMS software, this would be a substantial and burdensome change. Their general practice for the documents/records not requiring signature per the current 820 regulation is to simply enter the name of the responsible person and the date on the document/record, and not to require a signature (handwritten or electronic) for those documents/records.